Verve Therapeutics Inc

NEW
NAS:VERV (USA)  
$ 5.73 -0.06 (-1.04%) 04:00 PM EST
At Loss
P/B:
0.90
Market Cap:
$ 484.90M
Enterprise V:
$ -12.65M
Volume:
1.08M
Avg Vol (2M):
1.19M
Trade In:
Volume:
1.08M
At Loss
Avg Vol (2M):
1.19M

Business Description

Verve Therapeutics Inc
NAICS : 541714 SIC : 2833
ISIN : US92539P1012
Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 7.95
Equity-to-Asset 0.78
Debt-to-Equity 0.13
Debt-to-EBITDA -0.34
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.68
Distress
Grey
Safe
Beneish M-Score -0.81
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -36
3-Year EPS without NRI Growth Rate -25.8
3-Year FCF Growth Rate -23.1
Name Current Vs Industry Vs History
5-Day RSI 55.77
9-Day RSI 60.34
14-Day RSI 58.56
6-1 Month Momentum % -19.47
12-1 Month Momentum % -48.57

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.64
Quick Ratio 14.64
Cash Ratio 14.27

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -23.2
Shareholder Yield % -45.94

Financials (Next Earnings Date:2024-11-07 Est.)

VERV's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:VERV

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Verve Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 20.648
EPS (TTM) ($) -2.59
Beta 1.66
Volatility % 108.22
14-Day RSI 58.56
14-Day ATR ($) 0.375401
20-Day SMA ($) 5.32
12-1 Month Momentum % -48.57
52-Week Range ($) 4.305 - 20.12
Shares Outstanding (Mil) 84.62

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Verve Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Verve Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Verve Therapeutics Inc Frequently Asked Questions

What is Verve Therapeutics Inc(VERV)'s stock price today?
The current price of VERV is $5.73. The 52 week high of VERV is $20.12 and 52 week low is $4.31.
When is next earnings date of Verve Therapeutics Inc(VERV)?
The next earnings date of Verve Therapeutics Inc(VERV) is 2024-11-07 Est..
Does Verve Therapeutics Inc(VERV) pay dividends? If so, how much?
Verve Therapeutics Inc(VERV) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1